Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Johns Hopkins University |
---|---|
Information provided by: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT00127114 |
The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia.
Condition | Intervention | Phase |
---|---|---|
Dementia |
Drug: amantadine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) |
Estimated Enrollment: | 52 |
Study Start Date: | September 2005 |
Behavioral disturbances are a major cause of morbidity in frontotemporal dementia (FTD), yet little is known about the effectiveness of medications to treat these disturbances. Preliminary data suggests that the dopaminergic agent amantadine may reduce these disturbances. This 6-week, prospective, randomized, placebo-controlled trial will compare amantadine to placebo to assess its effectiveness in reducing behavioral symptoms.
Ages Eligible for Study: | 40 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Melanie Dieter, M.A. | 410-955-8702 | mdieter1@jhmi.edu |
Contact: David M Blass, M.D. | 410-955-6736 | dmblass@jhmi.edu |
United States, Maryland | |
Johns Hopkins University School of Medicine, Outpatient General Clinical Research Center | Recruiting |
Baltimore, Maryland, United States, 21287 | |
Contact: Gerald Stacy, B.A. 410-614-2717 Gerry@jhmi.edu | |
Principal Investigator: David M Blass, M.D. |
Principal Investigator: | David M Blass, M.D. | Johns Hopkins University |
Study ID Numbers: | 04033101 |
Study First Received: | August 3, 2005 |
Last Updated: | August 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00127114 |
Health Authority: | United States: Institutional Review Board |
Behavioral disturbance Frontotemporal dementia Dementia Amantadine Behavioral disturbance due to frontotemporal dementia |
Pick Disease of the Brain Speech Disorders Frontotemporal dementia Aphasia Central Nervous System Diseases Language Disorders Brain Diseases Aphasia, Primary Progressive Cognition Disorders Signs and Symptoms Dopamine |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Neurologic Manifestations Lobar atrophy of brain Primary progressive aphasia Amantadine Dementia Neurobehavioral Manifestations Pick disease of the brain Communication Disorders Delirium |
Anti-Infective Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Antiparkinson Agents Antiviral Agents |
Pharmacologic Actions Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Dopamine Agents Peripheral Nervous System Agents Analgesics Central Nervous System Agents |